Stable intraprostatic dihydrotestosterone in healthy medically castrate men treated with exogenous testosterone

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 7, 2016, Pages 2937-2944

  Thirumalai, Arthi ^a,c   Cooper, Lori A ^b   Rubinow, Katya B ^a   Amory, John K ^a   Lin, Daniel W ^c,d   Wright, Jonathan L ^c,d   Marck, Brett T ^e   Matsumoto, Alvin M ^a,c,e   Page, Stephanie T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Polyclinic ^*  (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; GONADORELIN ANTAGONIST; PLACEBO; TESTOSTERONE; ACYLINE; GONADORELIN; OLIGOPEPTIDE;

ACNE; ADULT; ANDROGEN THERAPY; ARTICLE; CASTRATION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRY SKIN; ERECTILE DYSFUNCTION; FATIGUE; HORMONE DETERMINATION; HOT FLUSH; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPOGONADISM; INJECTION SITE PAIN; LIBIDO DISORDER; LIQUID CHROMATOGRAPHY; MALE; NEEDLE BIOPSY; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE BIOPSY; RANDOMIZED CONTROLLED TRIAL; SKIN IRRITATION; TANDEM MASS SPECTROMETRY; TESTOSTERONE BLOOD LEVEL; ADVERSE EFFECTS; AGONISTS; DRUG EFFECTS; HEALTH; HORMONE SUBSTITUTION; METABOLISM; MIDDLE AGED; ORCHIECTOMY; PROCEDURES; PROSTATE; TREATMENT OUTCOME;

ADULT; DIHYDROTESTOSTERONE; GONADOTROPIN-RELEASING HORMONE; HEALTH; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; ORCHIECTOMY; PROSTATE; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84978401137     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-1483     Document Type: Article

References (40)

1. Tan RS, Salazar JA. Risks of testosterone replacement therapy in ageing men. Expert Opin Drug Saf. 2004;3(6):599-606.
2. Matsumoto AM. Fundamental aspects of hypogonadism in the aging male. Rev Urol. 2003;5(suppl 1):S3-S10.
3. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008; 93(1):68-75.
4. Vikan T, Schirmer H, Njølstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol. 2009; 161(3):435-442.
5. Vikan T, Schirmer H, Njølstad I, Svartberg J. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol. 2010;162(4):747-754.
6. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724-731.
7. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87(2):589-598.
8. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999;84(8):2647-2653.
9. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hy-pogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085-2098.
10. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34(4):828-837.
11. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624.
12. Spitzer M, Huang G, Basaria S, Travison TG, Bhasin S. Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol. 2013;9(7):414-424.
13. Cannata DH, Kirschenbaum A, Levine AC. Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab. 2012;97(2):360-365.
14. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf). 1994;40(3):341-349.
15. Isbarn H, Pinthus JH, Marks LS, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009;56(1):48-56.
16. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68(6):1263-1267.
17. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, et al. Endogenous sexhormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100(3):170-183.
18. Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median followup of 3 registries. J Urol. 2015;193(1):80-86.
19. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17(2):132-143.
20. Bhasin S, Woodhouse L, Casaburi R, et al. Testosterone dose-response relationshipsinhealthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181.
21. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022.
22. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006;91(10):3850-3856.
23. Mostaghel EA, Lin DW, Amory JK, et al. Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial. J Clin Endocrinol Metab. 2012; 97(8):2809-2817.
24. Page ST, Lin DW, Mostaghel EA, et al. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a ran-domized-controlled trial. J Clin Endocrinol Metab. 2011;96(2): 430-437.
25. Shahidi NT. Androgens and erythropoiesis. N Engl J Med. 1973; 289(2):72-80.
26. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1557; discussion 1564.
27. O'Leary MP, Fowler FJ, Lenderking WR, et al. A brief male sexual function inventory for urology. Urology. 1995;46(5):697-706.
28. Mostaghel EA, Nelson PS, Lange P, et al. Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol. 2014;32(3):229-237.
29. Roth MY, Page ST, Lin K, et al. Dose-dependent increase in intra-testicular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency. J Clin Endocrinol Metab. 2010;95(8):3806-3813.
30. Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 β to human plasma proteins at body temperature. J Steroid Biochem. 1982;16(6):801-810.
31. Swerdloff RS, Pak Y, Wang C, et al. Serum testosterone (T) level variability in T gel-treated older hypogonadal men: treatment monitoring implications. J Clin Endocrinol Metab. 2015;100(9):3280-3287.
32. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19): 2351-2361.
33. Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10(2):440-448.
34. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67(10):5033-5041.
35. Page ST, Hirano L, Gilchriest J, et al. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol. 2011;186(1):191-197.
36. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of andro-gen-dependent growth. Eur Urol. 2009;55(2):310-320.
37. Prout GR Jr, Brewer WR. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967;20(11):1871-1878.
38. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185(4):1256-1260.
39. Fernández-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6): 2560-2575.
40. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005; 90(2):678-688.